First-line FOLFOX versus carboplatin–paclitaxel in advanced esophageal squamous cell carcinoma: A retrospective comparative study from a tertiary hospital in Ethiopia.

Cancer of the esophagus, the tube that carries food from the throat to the stomach, is a formidable disease that strikes people across the globe. In many parts of the world, particularly in Asia and Africa, the most common form of this cancer is known as squamous cell carcinoma. This type of cancer often grows silently, and by the time symptoms appear, the disease has frequently spread beyond the point where surgery can remove it. When the cancer is advanced, doctors cannot cure it with a knife; instead, they rely on systemic therapy, which means using powerful drugs to travel through the bloodstream and attack cancer cells throughout the body. The goal is to shrink the tumors, slow their growth, and extend the patient's life. Two specific drug combinations have become standard tools for this job in many places: one mixes a platinum-based drug with a fluoropyrimidine, while the other pairs a platinum drug with a taxane. However, in regions like Sub-Saharan Africa, where resources are limited and the disease behaves differently than in Western countries, doctors have had to make choices based on guesswork rather than local evidence. They needed to know which of these two drug strategies actually worked better for the people living there.

In a recent study conducted at a major teaching hospital in Addis Ababa, Ethiopia, a team of researchers set out to answer this question by looking back at the records of patients treated between 2023 and 2025. They focused on fifty-five individuals who had been diagnosed with stage four esophageal squamous cell carcinoma, the most advanced stage of the disease. These patients had received one of the two main drug regimens as their first line of treatment. The researchers carefully tracked how the patients responded to the drugs, how long they lived, and what side effects they experienced. They were not just looking for a simple winner between the two drug mixes; they were also searching for clues about what factors, beyond the choice of medicine, might determine a patient's fate.

The study revealed that both treatment approaches were capable of shrinking tumors and offering hope. When the doctors evaluated the patients after several rounds of chemotherapy, nearly three-quarters of the group showed a positive response, meaning their tumors had either disappeared completely or shrunk significantly. Only a small fraction of patients saw their disease worsen while on treatment. When comparing the two specific drug combinations, the researchers found that the regimen containing carboplatin and paclitaxel appeared to be slightly more effective at shrinking tumors completely than the other regimen, which used oxaliplatin, leucovorin, and 5-fluorouracil. Patients receiving the carboplatin and paclitaxel mix saw complete tumor disappearance in sixteen percent of cases, whereas no one in the other group achieved this level of response. Furthermore, the group on carboplatin and paclitaxel experienced fewer instances where the cancer continued to grow despite treatment.

Despite these differences in how well the tumors shrank, the ultimate measure of success—how long the patients lived—did not show a clear advantage for either drug combination. The median survival time for the entire group was nine months, meaning half of the patients lived longer than this and half lived less. Those treated with carboplatin and paclitaxel lived a little longer on average than those on the other regimen, but the difference was so small that it could have happened by chance. The study concluded that neither drug regimen was definitively superior to the other when it came to extending life in this specific population.

However, the researchers discovered something far more significant than the choice of drugs. They found that two specific factors strongly predicted whether a patient would survive longer. The first was the timing of the treatment. Patients who experienced delays in receiving their scheduled chemotherapy doses had a much shorter survival time. Those who received their treatment without interruption lived significantly longer than those whose schedules were pushed back. The second factor was the patient's general physical condition before treatment began. Patients who were already struggling with daily activities, a state doctors measure as a specific performance status, had a much harder time surviving than those who were still active and independent. These findings suggest that for patients with advanced esophageal cancer in this region, keeping the treatment on schedule and ensuring the patient is strong enough to tolerate it are more critical to survival than the specific brand of chemotherapy chosen.

The study also highlighted the toll these powerful drugs take on the body. Half of the patients experienced delays in their treatment cycles, and the most common reason was a drop in healthy blood cells, a condition known as neutropenia, which leaves the body vulnerable to infection. While both drug combinations caused side effects, they did so in different ways. The carboplatin and paclitaxel mix was more likely to cause severe drops in blood cell counts, while the other regimen was more frequently associated with nerve damage, which can cause numbness or tingling in the hands and feet.

Ultimately, this research provides a clear picture of the reality for patients with advanced esophageal cancer in Ethiopia. While the medical community has long debated which drug combination is best, this study suggests that for these patients, the choice between the two standard regimens matters less than the ability to deliver the treatment on time and the patient's baseline health. The researchers noted that the carboplatin and paclitaxel regimen might be preferred by some doctors simply because it requires fewer visits to the hospital, as it is given every three weeks rather than every two, and it showed a slightly better rate of tumor shrinkage. However, the most important lesson from the data is that proactive care to prevent treatment delays and to support patients' physical strength could save more lives than switching drug formulas. The study calls for larger, future investigations to confirm these findings, but for now, it offers a vital guide for doctors working in resource-limited settings, emphasizing that consistency and patient support are the true keys to improving outcomes.